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Abstract
CYP4B1 belongs to the cytochrome P450 family 4, one of the oldest P450 families whose
members have been highly conserved throughout evolution. The CYP4 monooxygenases
typically oxidize fatty acids to both inactive and active lipid mediators, although the endoge-
nous ligand(s) is largely unknown. During evolution, at the transition of great apes to
humanoids, the CYP4B1 protein acquired a serine instead of a proline at the canonical posi-
tion 427 in the meander region. Although this alteration impairs P450 function related to the
processing of naturally occurring lung toxins, a study in transgenic mice suggested that an
additional serine insertion at position 207 in human CYP4B1 can rescue the enzyme stabil-
ity and activity. Here, we report that the genomic insertion of a CAG triplet at the intron
5–exon 6 boundary in human CYP4B1 introduced an additional splice acceptor site in
frame. During evolution, this change occurred presumably at the stage of Hominoidae and
leads to two major isoforms of the CYP4B1 enzymes of humans and great apes, either with
or without a serine 207 insertion (insSer207). We further demonstrated that the CYP4B1
enzyme with insSer207 is the dominant isoform (76%) in humans. Importantly, this amino
acid insertion did not affect the 4-ipomeanol metabolizing activities or stabilities of the native
rabbit or human CYP4B1 enzymes, when introduced as transgenes in human primary cells
and cell lines. In our 3D modeling, this functional neutrality of insSer207 is compatible with
its predicted location on the exterior surface of CYP4B1 in a flexible side chain. Therefore,
the Ser207 insertion does not rescue the P450 functional activity of human CYP4B1 that
has been lost during evolution.
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Introduction
Cytochrome P450s (CYPs) constitute a large superfamily of genes that have co-evolved with
their hosts—higher plants, prokaryotic and eukaryotic organisms—from a single common
ancestor [1, 2]. In humans, the HUGO Gene Nomenclature Committee currently lists 107
genes and pseudogenes (http://www.genenames.org/genefamilies/CYP) belonging to 4 major
and 13 smaller P450 families [3]. Although there are remarkably similar substrate specificities
for the vast majority of P450 orthologs in mammals due to semi-conserved active-site
sequences and ligand access channels [4], human CYP4B1 stands out as a functionally unusual
member of this single-gene subfamily (reviewed in [5]).
CYP4B1 was initially recognized as the P450 enzyme responsible for the activation of a nat-
urally occurring pro-toxin, 4-ipomeanol (4-IPO), to an alkylating agent [6–10]. 4-IPO is pro-
duced by sweet potatoes (Ipomoea batatas) infected with the fungus Fusarium solani [11–14].
When livestock ingest moldy sweet potatoes, 4-IPO uptake induces selective cellular toxicity in
the lungs as the primary organ affected [11, 12, 14] where 70% of all CYP4B1 transcripts are
expressed [15–18]. Based on the preclinical observations in rodents and dogs that doses can be
established where the cytotoxicity is restricted to the lungs and the findings that human lung
cancer cells in vitro and in vivo can be specifically targeted (reviewed in [19]), three human
clinical phase I/II trials were conducted [20–22]. Surprisingly, dose-escalation studies revealed
that no lung toxicity, but some reversible dose-dependent liver toxicity occurred after intrave-
nous administration of 4-IPO. However, no objective anti-tumor effects were noted, for either
lung or liver cancer patients [20–22].
Major interspecies differences in the activity of CYP4B1 enzyme between the human and
other mammalian homologs have been reported (reviewed in [5]). When overexpressed in
human HepG2 liver cells, the native human CYP4B1 enzyme is unable to metabolize the classi-
cal substrates such as 2-aminoanthracene (2-AA) [23, 24] and 4-IPO [9, 25]. In addition, no
catalytic activity of the human enzyme was detected upon its expression in insect cells using a
baculovirus system [26], presumably because the human enzyme sequence carries serine
instead of proline at position 427 in the meander region near the heme-binding site [26, 27].
Remarkably, the presence of serine instead of proline at position 427 is specific to human
CYP4B1 and also unique among other human CYP450 enzymes [5, 28].
In addition to the initially identified human cDNA sequence [25], three groups of investiga-
tors reported an in-frame insertion in the major CYP4B1 transcript isolated from several
human tissues [29–31]. Bylund et al. performed RT-PCR studies on four human seminal vesi-
cle samples and detected a mixture of the native CYP4B1 and an isoform with a 3-bp insertion
(CAG) encoding serine at position 207 in all samples [29]. Carr et al. suggested that the serine
insertion is the result of an alternatively splice transcript but was not able to find a transcript
without serine at position 207 in five bacterial clones amplified from human lung [31]. In these
studies, the functional significance of the serine insertion was not determined, because it was
not possible to express active human CYP4B1 enzyme, either with or without the serine inser-
tion [31]. In 2001, Imaoka et al. reported that the serine insertion was carried by the CYP4B1
‘gene’ in 50 different individuals [30], suggesting that it is the major transcript in humans,
although no supporting data were presented. This group was also able to express human
CYP4B1 insSer207 in the liver of a transgenic mouse and as a fusion protein of CYP4B1 and
NADPH P450 reductase in yeast cells [30]. The microsomal preparations containing the
human protein catalyzed ω-hydroxylation of lauric acid and activated 2-AF, both known sub-
strates for CYP4B1, thus prompting the authors to hypothesize that the serine insertion “may
also stabilize the native CYP4B1” [30]. However, these findings regarding a functional activity
of native human CYP4B1 with the serine insertion towards classical substrates of animals
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orthologs have not been confirmed by others (reviewed in [5]) and are in sharp contrast to the
results of phase I/II dose escalation trials in humans in which 4-IPO was administered as an
anti-lung cancer agent [20–22]. Although humans express 70% of all CYP4B1 transcripts in the
lung [29–32], no lung toxicity was observed with administration of 4-IPO doses that are highly
toxic/lethal in animals [17, 19, 33, 34].
To clarify some of these issues, we recently re-engineered human CYP4B1 for efficient acti-
vation of 4-IPO by introducing amino acid residues from the highly active rabbit enzyme into
the native human protein as well as the p.S427P CYP4B1 mutant [28]. Using lentiviral vector
systems to achieve stable expression of human and rabbit CYP4B1 in human HepG2 liver cells
and primary T cells, we demonstrated that native human CYP4B1 is an inactive and relatively
unstable protein with a short half-life compared to its rabbit homolog. Exchange of serine with
proline at position 427 improved the half-life of the human CYP4B1 protein and dramatically
increased its enzymatic activity towards 4-IPO, although this single point mutant was still less
active than the rabbit enzyme. Eventually, through systematic mutagenesis, we identified 12
additional amino acid substitutions that conferred all of the functional activity of rabbit
CYP4B1 to human CYP4B1 [28]. These prior efforts establish a baseline against which to
probe the functional consequences of insSer207 in CYP4B1.
In the present study, we analyzed the molecular basis for serine insertion at position 207 in
the human CYP4B1 enzyme and determined the frequency of insSer207 in human CYP4B1 tran-
scripts. In order to determine whether insSer207 could have emerged as a compensatory mecha-
nism for reduced P450 enzymatic activity due to a p.P427S exchange that had occurred in
humans, we tested whether insSer207 stabilizes the half-life and/or enhances the functional activ-
ity of native human CYP4B1 and the p.S427P CYP4B1 mutant proteins. Finally, we explored the
evolution of the human CYP4B1 genomic sequence through comparison of insSer207 and p.
P427S in humans to those in great apes and non-human primates as well as other mammals.
Materials and Methods
Serine insertion in normal human CYP4B1mRNA
To assess the frequency of the serine insertion in human CYP4B1mRNA (Fig 1A), a PCR was
performed on human reference cDNA (Clontech #636690, Lot #1005341A) using the exon 4
forward primer 5'-GCCTCGAGGGTTGCAGCACCGCAAGCTG with the XhoI restriction
enzyme recognition site (bold) and the exon 9 reverse primer 5'- GGGCTAGCCACAGGTGGG
TAGAGGCGG with the NheI site (Fig 2A). PCR products of 740 and 743 bp were ligated into
the multiple cloning site (mcs) of the lentiviral vector IRES-EGFP with an internal ribosome
entry site—enhanced green fluorescent protein (Fig 3A) and then transformed into Top10 bac-
teria (Invitrogen, Karlsruhe, Germany). Plasmid DNA was isolated from 220 bacterial clones
and sequenced using the forward primer 5'- GGACCTGAAATGACCCTGCG that binds in the
spleen focus-forming virus (SFFV) promoter.
Cell cultures and primary cells
Human embryonic kidney (HEK293T) cells and human hepatoma (HepG2) cells were pur-
chased from ATCC (Manassas,VA), and human fibrosarcoma HT1080 cells were obtained
from DSMZ (Braunschweig, Germany). All cells were grown in Dulbecco’s Modified Eagle’s
Medium supplemented with penicillin (100 U/mL), streptomycin (100 μg/mL), 2 mM gluta-
mine (all from Gibco/BRL, Karlsruhe, Germany), and 10% heat-inactivated fetal bovine serum
(PAN, Aidenbach, Germany) at 37°C in a humidified atmosphere with 5% CO2.
Primary human T lymphocytes from peripheral blood (PB) samples from healthy adult vol-
unteers who provided written informed consent that is documented in the department of
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Fig 1. Alternative Splicing of CYP4B1. (A) HumanCYP4B1. The human CYP4B1 intron 5–6 harbors two
splice acceptors (SAs) in frame allowing the generation of two alternative CYP4B1 transcripts, with (isoform
2: NM_001099772) or without (isoform 1: NM_000779) insSer207. (B) RabbitCYP4B1. Intron 5–6 of rabbit
CYP4B1 carries only a single SA and therefore generates a single transcript without insSer202 (isoform 1:
NM_001082103). (C) Alignment ofCYP4B1 sequences from other species. Alignment of the genomic DNA of
CYP4B1 from other species shows that the insertion of the CAG triplet, which generates the additional splice
acceptor site, exists only in humans and great apes, and not in rhesus, macaque, marmoset or other
mammals.
doi:10.1371/journal.pone.0137110.g001
Fig 2. Frequency of insSer207 in humanCYP4B1 transcripts. (A) Schematic outline of CYP4B1. The
forward (fw) primer binds in exon 4 and the reverse (rv) primer in exon 9, thus resulting in PCR products of
240 bp and 243 bp, respectively. (B) Frequency of human CYP4B1 without (w/o) and with insSer207. The
plasmid DNA from 220 bacterial colonies was isolated and sequenced. The percentages of CYP4B1
transcripts with and without (w/o) insSer207 are shown.
doi:10.1371/journal.pone.0137110.g002
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Otorhinolaryngology & head/neck surgery (ENT). This study including the documentation
was approved by the ethics committee of the Heinrich-Heine-University of Düsseldorf (ethics
No. 4687). After Ficoll-Hypaque density gradient centrifugation, outgrowth of>95% T cells
was achieved by incubation of the mononuclear cells on immobilized CD3 and CD28 antibod-
ies (BD Bioscience, San Jose, CA) in combination with IL-2 (100 IU/ml, Chiron, Marburg, Ger-
many) in complete Iscove’s Modified Dulbecco’s Medium (Sigma-Aldrich, Deisenhofen,
Germany) as described previously [28, 35, 36].
Plasmid construction, lentivirus production, and cell transduction
The two lentiviral expression plasmids IRES-EGFP (used in Fig 3A and for Fig 4) and IRES--
NeoR (Fig 5A) as well as expression constructs for the native rabbit CYP4B1 (NM_001082103,
isoform 1), the wild-type human CYP4B1 (NM_000779, isoform 1), and the mutant human p.
Fig 3. Functional analysis of CYP4B1. (A) Schematic outline of the lentiviral (LV) vectors used for
expression of CYP4B1. For functional testing, the different CYP4B1 forms were cloned into a LV vector with
an IRES-EGFP site. CMV: CMV promoter; SD: splice donor; LTR: long terminal repeat; SA: splice acceptor;
RRE: Rev responsive element, cPPT: central polypurine binding tract; SFFV U3: U3 promoter of the spleen
focus-forming virus; mcs: multicloning site; IRES: internal ribosomal entry site; EGFP: enhanced green
fluorescent protein. (B) Toxicity of HepG2 cells after 4-IPO exposure. Survival of EGFP+ HepG2 cells (%)
after 24 and 48 h of incubation with 0, 2.9, 29, 290 or 1450 μM 4-IPO as measured by flow cytometry. The
cells stably expressed the different CYP4B1 enzymes: h-S427: human wild-type (isoform 1); h-S427
insSer207: human wild-type with insSer207 (isoform 2), h-P427: human mutated p.S427P (artificial); h-P427
insSer207: humanmutated p.S427P with insSer207 (artificial); r-P422: rabbit wild-type (isoform 1); r-P422
insSer202: rabbit with insSer202 (artificial). For each construct, the mean ± standard error of the mean (SEM)
values are shown from at least three independent experiments. The transduction efficiency of HepG2 cells
(not shown) was90%, as determined by EGFP expression in flow cytometry. (C) Toxicity of T cells after
4-IPO exposure. Survival of EGFP+ primary human T cells (%) expressing the different CYP4B1 proteins
[listed for (B)] after 24 and 48 h of incubation with increasing doses of 4-IPO as assessed by flow cytometry.
For each construct, the mean ± SEM values are shown from at least three experiments.
doi:10.1371/journal.pone.0137110.g003
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S427P were described previously [28]. For insertion of serine at position 207 in the two human
CYP4B1 proteins (NM_001099772: wild-type with insertion, isoform 2) and at position 202 in
the rabbit enzyme, a commercial site-directed mutagenesis kit (Stratagene, La Jolla, CA) was
used according to the manufacturer’s recommendations with the following primers 5'-
CGGCCTGGGCCACAGCAGGGACAGCAGCTACTACC (forward) and 5'-GGTAGTAGCTG
CTGTCCCTGCTGTGGCCCAGGCCG (reverse) for human CYP4B1 and 5'-GGAGACAGTG
GCCTGAATCACAGCAGGGACAGCAGCTACTACGTG (forward) and 5'- CACGTAGTAGC
TGCTGTCCCTGCTGTGATTCAGGCCACTGTCTCC (reverse) for rabbit CYP4B1. The cDNAs
with a serine insertion, either with or without a 3'EGFP fusion, were then cloned into the
IRES-NeoR and IRES-EGFP constructs, respectively, using the NheI-BamHI restriction
enzyme sites in the vectors. The final lentiviral expression constructs were verified by Sanger
sequencing.
Vesicular stomatitis virus G (VSV-G) pseudotyped replication-deficient lentiviral particles
were then produced after transfection into HEK293T cells and cryopreserved as described pre-
viously [28, 37]. Functional titers of the supernatants were assessed on HT1080 cells. HepG2
cells were transduced with either IRES-EGFP or IRES-NeoR vectors using 8 μg/ml polybrene
(Sigma-Aldrich) [28, 37]. Primary human T cells were transduced in the presence of 100 U/ml
IL-2 on the recombinant fibronectin fragment CH-296 (Takara Shuzo, Otsu, Japan) as previ-
ously described [28, 35, 38, 39].
Toxicity assay with 4-IPO
Five days after transduction of the HepG2 cells and four days after transduction of the T lym-
phocytes, cells were incubated in complete medium with increasing concentrations of 4-IPO
(0, 2.9, 29, 290, and 1450 μM). Cultures were harvested after 24 and 48 h, centrifuged, and then
re-suspended in PBS with propidium iodide (PI; Sigma-Aldrich). Each sample was then ana-
lyzed by flow cytometry on a FACSCalibur (BD Biosciences, Heidelberg, Germany), and
Fig 4. Bioactivation of 4-IPO to a stable NAC/NAL adduct. The NADPH-dependent formation of NAC/NAL
adducts by membranes isolated from HepG2 cells stably transduced with the different CYP4B1 cDNAs r-
P422: rabbit wild-type (isoform 1); h-S427: human wild-type (isoform 1); h-P427: human mutated p.S427P
(artificial); h-S427 insSer207: human wild-type with insSer207 (isoform 2) after incubation in 50 nM 4-IPO for
20 minutes is shown. The adduct formation rate is shown as the mean ± standard deviation (SD) of triplicate
incubations.
doi:10.1371/journal.pone.0137110.g004
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10,000 events were recorded. Live/dead cell analysis of EGFP+ cells was then performed using
the CellQuest software as previously described [28]. Each experiment was performed indepen-
dently at least three times.
CYP4B1-dependent NAC/NAL adduct formation and quantitative
analysis
In vitro bioactivation of 4-IPO by human CYP4B1 enzyme was assessed by incubating mem-
brane preparations (1 mg) from transduced stably expressing HepG2 cells in the presence of
substrate (1 mM), NADPH (1 mM), and both N-acetylcysteine (NAC) and N-acetyllysine
(NAL) at 5 mM concentrations. Incubations were conducted at 37°C for 30 min, and adduct
formation was quantified by a high performance liquid chromatography ultraviolet detector as
previously described [40]
Protein half-life analysis
For determination of the protein half-lives, we used 3'EGFP-fusion CYP4B1 proteins in the
lentiviral IRES-NeoR vector (Fig 5A) as described previously [28]. Briefly, G418-resistant
HepG2 cells were incubated with 50 μg/ml cycloheximide (CHX, Sigma-Aldrich), which inhib-
its eukaryotic protein translation. After 5, 10, 25, and 35 h, cells were harvested and fixed in 4%
paraformaldehyde and, the mean fluorescence intensity (MFI) was assessed by flow cytometry.
Fig 5. Protein stability of CYP4B1. (A) Schematic outline of the lentiviral vector used for expression of
CYP4B1. CMV: CMV promoter; SD: splice donor; LTR: long terminal repeat; SA: splice acceptor; RRE: Rev
responsive element, cPPT: central polypurine binding tract; SFFV U3: U3 promoter of the spleen focus-
forming virus; mcs: multicloning site; IRES: internal ribosomal entry site; neoR: neomycin
phosphotransferase (nptII) resistance cDNA; EGFP: enhanced green fluorescent protein. (B) Protein half-life
analysis of CYP4B1 isoforms in HepG2 cells. Protein half-life analysis was performed by adding 50 μg/ml
cycloheximide (CHX) to the transduced and G418-selected HepG2 cells. The mean fluorescence intensity
(MFI) of CYP4B1/EGFP fusion proteins was assessed at various time points by flow cytometry. For each
construct, the mean ± SEM values are shown from at least three experiments.
doi:10.1371/journal.pone.0137110.g005
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The MFI values of cells treated with CHX were expressed as a percentage of the MFI of cells
incubated in medium without CHX. Each experiment was performed independently at least
three times.
Modeling of human CYP4B1
Structural modeling of human CYP4B1 with insSer207 was performed using the Robetta server
[41–43] that used the X-ray structure of a bacterial mimic of CYP2C9 (pdb id: 3QI8) as a tem-
plate. Sequence identity between human CYP4B1 and the bacterial mimic of CYP2C9 was
~24%. A total of 5,000 models were generated followed by model clustering. The best CYP4B1
models were chosen based on the centers of the largest clusters and defined by having the low-
est standard mean deviation value (between corresponding positions of C-α atoms of all resi-
dues) among all other models in a cluster.
Results
Evolution of the additional splice acceptor site in CYP4B1
To understand the molecular basis for alternative CYP4B1 transcripts that do or do not encode
insSer207, we first analyzed the splice donor and acceptor sites in intron 5 of human and rabbit
CYP4B1. As shown in Fig 1A, the human genome harbors two splice acceptor sites in frame
before exon 6, thus allowing the generation of two alternative transcripts, with or without ser-
ine at position 207, respectively. In contrast, intron 5 of the rabbit gene (Fig 1B) carries only a
single splice acceptor site at the corresponding exon 6 boundary and therefore generates a sin-
gle transcript without serine at amino acid position 202. Next, we aligned the genomic DNA of
the corresponding CYP4B1 intron 5 sequences of great apes, monkeys, and other mammals
obtained from the ensembl genome database (www.ensembl.org). The alignment in Fig 1C
revealed that an insertion of a CAG triplet, generating the additional splice acceptor site,
occurred during evolution at the level ofHominoidae (Homo sapiens and apes) and clearly dis-
tinguishes these species from old world (rhesus macaque) and new world (marmoset) monkeys.
Other mammals such as rat, cow, and elephant also do not have the alternative splice acceptor
site, thus making insSer207 specific for Hominoidae.
Ratio of CYP4B1 transcripts in healthy human tissues
To determine the usage of the two different splice acceptor sites of CYP4B1 in human tran-
scripts, a PCR with the primer pair shown in Fig 2A was performed on a commercial human
cDNA library that was pooled from the mRNA of various organs obtained from 81 healthy
donors. The PCR products were cloned into a high copy number plasmid, and the DNA inserts
in bacterial colonies were isolated and sequenced. As shown in Fig 2B, 169 out of 220 (76.8%)
bacterial clones contained insSer207, whereas 51 clones (23.2%) did not. Thus, the majority of
translated human CYP4B1 contains insSer207.
Functional analysis of human and rabbit CYP4B1 with/without
insSer207/202
The enzymatic activation of 4-IPO is an established tool for assessing and comparing the activ-
ity of CYP4B1 orthologs. To evaluate the functional consequences of insSer207/202 on the
activity of the CYP4B1 enzyme, PCR was used to introduce the CAG sequence, containing the
additional splice acceptor site, into the human native and mutant p.S427P CYP4B1 enzymes at
the intron 5–exon 6 boundary. We also introduced the serine insertion at the corresponding
position 202 of the native rabbit CYP4B1 protein (insSer202). For stable expression in
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mammalian cells, all six cDNAs were cloned into the lentiviral expression vector IRES-EGFP
(Fig 3A), thus linking the expression of the CYP4B1 cDNAs to EGFP as a marker gene for
transduced cells [28]. Replication-deficient lentiviral particles pseudotyped with VSV-G were
titered as described previously [28, 37] and used to transduce human HepG2 liver cells with
the different constructs at similar viral particle per target cell, also called multiplicities-of-infec-
tion (MOIs) of approximately 5–7. The results demonstrated that HepG2 cells transduced with
the control vector did not show any cell death in response to the increasing 4-IPO concentra-
tion after 24 and 48 h (Fig 3B), because bioactivation could not occur. Moreover, as shown pre-
viously [28], the native human CYP4B1 enzyme was not capable of processing 4-IPO, while
both the rabbit wild-type and the human p.S427P mutant CYP4B1 induced clear cytotoxic
effects on the cells. Finally, introduction of serine at corresponding positions into the wild-type
rabbit or human p.S427P CYP4B1 did not alter the high activities of both enzymes towards
4-IPO (Fig 3B).
To confirm these findings in non-transformed cells that do not express CYP4B1mRNA
(Wiek & Hanenberg, unpublished), primary human T cells from healthy donors were isolated,
transduced with the same vectors at similar MOIs, and then challenged with increasing doses
of 4-IPO. After 24 and 48 h, the cells were harvested, and the survival of transduced EGFP+ T
cells was analyzed by flow cytometry. As shown in Fig 3C, the insSer207/202 did not restore
the negligible activity of the native human CYP4B1 enzyme nor alter the strong metabolizing
activities of the wild-type rabbit or the mutant human p.S427P CYP4B1 proteins. Therefore
identical to the results obtained in HepG2 cells, the serine insertion did not alter the enzymatic
activity of neither the wild-type rabbit and human nor the mutant human CYP4B1 protein.
4-IPO induced adduct formation and cellular cytotoxicity
As survival of stably transduced human cells was used as the indicator for CYP4B1 enzyme
activity towards 4-IPO, we wanted to confirm that a direct correlation exists between the per-
centage of EGFP+ cells that survived after 4-IPO incubation and 4-IPO adduct formation in
these cells. To this end, we assessed NAC/NAL adduct formation in membrane preparations
from HepG2 cells stably transduced with the rabbit or one of the three human CYP4B1 cDNAs.
Just as 4-IPO was not toxic to cells expressing wild-type human CYP4B1 (Fig 3B), membranes
prepared from these cells did not catalyze the bioactivation of 4-IPO (Fig 4). However, when the
serine in the meander region was reverted to the evolutionarily conserved proline at position
427 (p.Ser427Pro), 4-IPO was bioactivated and formed NAC/NL adducts (Fig 4). The very
active rabbit enzyme served as a positive control. The results clearly demonstrated that both
assays, cell survival and NAC/NAL adduct formation, are well suited for measuring the 4-IPO
metabolizing activity of different CYP4B1 enzymes. Importantly, both assays also showed that
the insSer207 variant of human CYP4B1 does not ‘rescue’ the loss of enzyme activity towards
xenobiotics caused in large part by the presence of the meander region amino acid, Ser427.
Protein stability of human and rabbit CYP4B1 with or without serine
insertion
We have previously shown that the differences in the 4-IPO metabolizing activity of the wild-
type rabbit and human mutant CYP4B1 enzymes is caused, at least in part, by differences in
protein half-life and expression level [28]. Given that Imaoka et al. suggested that the function
of insSer207 may be to stabilize the native human CYP4B1 enzyme [30], we next tested the
effect of this insertion on the half-lives and expression levels of the native rabbit and human
CYP4B1 proteins. We also included the human CYP4B1 p.S427 mutant with and without ins-
Ser207 as additional controls.
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As no antibody is available that can recognize both the human and the rabbit proteins
equally well, 30EGFP-CYP4B1 fusion proteins were cloned into a lentiviral vector with an
IRES-NeoR cassette (Fig 5A) as described previously [28]. HepG2 cells were transduced at sim-
ilar MOIs of approximately 3 with the infectious lentiviral particles stably expressing the differ-
ent fusion enzymes and then selected with G418 (Geneticin
1
). G418-resistant HepG2 cells
were incubated with cycloheximide (CHX) and then harvested at several time points to semi-
quantitatively assess the mean fluorescent intensities (MFIs) of the CYP4B1-EGFP fusion con-
structs by flow cytometry. Similarly to our previously reported findings [28], HepG2 cells
expressing the native rabbit CYP4B1 showed the highest MFI (500 on the FL1 channel) of all
EGFP-tagged proteins and the smallest decline during the observation period (t1/2>75 h).
These characteristics of the wild-type rabbit protein were not influenced by insSer202. The
analysis further demonstrated that the corresponding insSer207 in the human protein also did
not influence the half-life and expression level of either the native (t1/2 ~7h) or the mutant p.
S427P (t1/2 ~13h) CYP4B1 protein (Fig 5B, pairs of solid versus hatched lines).
Structural models of the serine insertions in human and rabbit CYP4B1
Finally, to better understand why insSer207 had no effect on the expression level, half-life, or
enzymatic activity of the three CYP4B1 proteins, we generated a three-dimensional model for
insSer207 in human CYP4B1. Because no crystal structure is available for any CYP4 protein, we
used the Rosetta-based Robetta server to generate a homology model. The model shown in Fig 6
localizes insSer207 to a loop region, distant from the heme catalytic center, that is comprised by
residues G198 to S210. Within this loop, the Ser207 side-chain is oriented away from the active
site towards the soluble environment. These structural features are consistent with insSer207
having a minimal effect on human CYP4B1 structure and catalysis. Similar structural consider-
ations also apply for the rabbit wild-type and human p.S427P CYP4B1 proteins (not shown).
Discussion
Human CYP4B1 has been described as an enigmatic enzyme [5], in part due to the two
human-specific serine residues that have been incorporated into the primary sequence during
Fig 6. Structural model of human CYP4B1 with insSer207 located in a loop region fromG198 to S210.
Cartoon representation of the structure of human CYP4B1. The side chain of insSer207 and the heme
prosthetic group are shown as spacefilling and ball and stick representations, respectively. Carbon atoms are
colored gray, oxygen atoms are colored red, nitrogen atoms are colored blue, and hydrogen atoms are
colored white. The figure was generated using UCSF Chimera [43].
doi:10.1371/journal.pone.0137110.g006
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evolution. One unanswered question regarding CYP4B1 in the literature is the importance of
insSer207 in human CYP4B1 and its role in the function of the enzyme. Although not
described in the initial cloning of the human CYP4B1 cDNA [25], three groups subsequently
described insSer207 as the major form of CYP4B1mRNA in human tissues [29–31]. Carr et al.
reported that only this insertion was present in 5 out of 5 bacterial clones, but a more in-depth
semi-quantification of the ratio of the two isoforms was not performed in any of the earlier
studies. In the present work, after sequencing a library of exon 5-exon 6 amplified CYP4B1
cDNA fragments, we demonstrated that the insSer207 is encoded by 76% of CYP4B1 tran-
scripts in humans. This insertion is the consequence of a CAG triplet that was introduced at
the intron-exon junction of intron 5–6, thereby creating a second functional splice acceptor
site for exon 6 in frame.
Imaoka et al. put forward the intriguing idea that insSer207 in native human CYP4B1 might
have occurred to restore the enzyme function by compensating for the negative consequences
of the p.P427S alteration that had occurred in humans during evolution [30]. We therefore
functionally tested the serine insertion in three different CYP4B1 enzymes with well defined
functional activities towards 4-IPO: i) the native rabbit protein, in which serine was artificially
introduced at the corresponding amino acid position 202; ii) the native human CYP4B1; and
iii) the mutant human CYP4B1 p.S427P enzyme, in which the canonical proline present in
other CYP450s at corresponding positions was re-introduced in place of serine. For the latter
protein, we recently reported that this p.S427P amino acid change restored the metabolizing
activities of the human protein for hallmark substrates of animal CYP4B1 enzymes [28]. The
results of the present study clearly demonstrate that insSer207 in the two human proteins and
insSer202 in the rabbit enzyme have no functional impact on the bioactivation of 4-IPO in
human primary cells and cell lines. In addition, the insertion did not alter the CYP4B1 expres-
sion level or half-life when stably expressed in HepG2 cells. Importantly, in contrast to the
hypothesis by Imaoka et al. [30], insSer207 did not restore the absent enzymatic activity of
native human CYP4B1 with serine at position 427 for 4-IPO. Thus, insSer207 in the human
mutant p.S427P and insSer202 in the wild-type rabbit CYP4B1 seem to be neutral modifica-
tions regarding the xenobiotic metabolizing capabilities of human and animal CYP4B1s.
The homology model for human CYP4B1 mapped insSer207 to a peripheral loop region,
and although this localization might support some local structural perturbation, insSer207
clearly does not affect any of the functional read-outs for the three pairs of enzymes studied
here (Figs 3–5). In addition, the phylogenetic analysis demonstrated that during evolution, the
insertion of a CAG repeat in intron 5 had already occurred at the stage of hominoidae and is
therefore present in all great apes and humans (data on the CYP4B1 locus in gibbons as lesser
great apes are not available in public databases). As the p.P427S ‘variant’ is unique to humans
and arose later in evolution than insSer207, the latter has no possible role in rescuing defective
human CYP4B1 enzyme activity.
For more than 25 years now, the role and function of the human CYP4B1 has remained a
mystery. Retrospectively, this uncertainty seems to be the consequence of a combination of fac-
tors, predominantly i) technical difficulties in reliably expressing the native human CYP4B1
enzyme in human cells and thus in performing functional analyses, ii) contradictory results in
heterologous expression systems such as insect cells and liver cells of transgenic mice, and iii)
the absence of known functions for CYP4B1 in mammals and lower organisms. However, in
the last 2 years, we have made considerable progress towards achieving a better understanding
of the structure–function relationships for human CYP4B1. Previously, we demonstrated that
compared to the very active rabbit CYP4B1 enzyme, the human protein lacks important amino
acid determinants in the middle domain of the protein that can render even the human native
protein with serine at position 427 able to actively process 4-IPO [28]. Here, we have
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demonstrated that the two naturally occurring human CYP4B1 isoforms, with/without ins-
Ser207, have no 4-IPO bioactivating ability. Therefore, we can safely conclude that the native
human CYP4B1 enzyme lost its enzymatic activity against typical xenobiotic pneumotoxins
during evolution and therefore is now an ‘orphan’ P450 enzyme in humans. However, it should
be noted that it still remains unclear which functional role(s) the active CYP4B1 homologs in
great apes and other mammals might have, especially for endogenous substrates.
Finally, the conclusion, that the human CYP4B1 protein, with or without the serine inser-
tion, is unstable, non-functional, and thus redundant in humans fits well with the relatively
high frequency of detrimental genetic polymorphisms found in two human studies [44, 45].
Lo-Guidance et al. detected five allelic variants of CYP4B1 in a French Caucasian population
with the second most frequent, CYP4B12, present in 518 out of 2082 (24.9%) French-Cana-
dian individuals. This allele represents a 2-bp deletion (c.881-2delAT) that results in a prema-
turely terminated protein [44]. Forty study participants (2%) carried this non-functional allele
in the homozygous state [44]. Hiratsuka et al. reported that the frequency of a CYP4B1 allele
with the same 2-bp deletion is 33.3% in the Japanese population and that 18 out of 192 (9.4%)
individuals are homozygous [45]. These high frequencies of other non-functional CYP4B1
alleles support the theory that the gene is redundant in humans and therefore not subject to
further genetic selection [46].
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